Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dolutegravir + lamivudine + tenofovir disoproxil fumarate (Aidi Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- 江苏艾迪药业
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ADC205 is a fixed-dose combination tablet developed by Jiangsu Aidea Pharma for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing 35 kg or more. It is formulated as a single-tablet regimen containing three established antiretroviral agents: dolutegravir sodium (50 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg). Dolutegravir acts as an integrase strand transfer inhibitor (INSTI), while lamivudine and tenofovir disoproxil fumarate function as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). By combining these three mechanisms of action, ADC205 aims to simplify daily medication regimens, reduce pill burden, improve patient adherence, and minimize the risk of viral resistance. The drug is currently in Phase 1 clinical development in China.
- Brand names
- AcriptegaDamicavaDovimilEmdoltenLanogravLavernLuvigenMilutinNuvacoOdystraRanegaReydinTeladoTelatriTemivTladeezViripilVolutripVulante
- Other names
- DTG/3TC/TDFTLDdolutegravir, lamivudine, and tenofovir disoproxil fumaratedolutegravir/lamivudine/tenofovir disoproxil fumarate
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseIntegrase allosteric pocket (HIV)
Beyond the preview
Go deeper on dolutegravir + lamivudine + tenofovir disoproxil fumarate (Aidi Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dolutegravir + lamivudine + tenofovir disoproxil fumarate (Aidi Pharmaceutical).